Preclinical
New research is shedding some light on how the brain responds when people are feeling sad, which could lead to new methods of treating some mood disorders. A research team from the University of California, San Francisco (UCSF) reported in an article in Cell that a network defined by amygdala-hippocampus β-coherence predicts mood in 13 of 21 subjects.
The mice had been genetically modified to have symptoms similar to Alzheimer’s. They were given a synthetic version of tetrahydrocannabinol (THC) for six weeks. In their study, the mice receiving the THC performed as well on a memory test as the healthy mice.
One of the biggest areas of research when it comes to cancer is prediction, because the sooner cancer is detected, the higher the chance that the patient will survive. In most cases, cancer is diagnosed after it has already entered into the advanced stages, which severely decreases the effectiveness of current cancer treatments.
The Baltimore Longitudinal Study of Aging was launched in 1958 by the National Institutes of Health. The idea was to follow and study the lives of healthy, active people over their lifetimes, rather than after they were dead.
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
In its recent third-quarter report, Cambridge, Mass.-based Intellia Therapeutics indicated it is delaying its submission of an Investigational New Drug (IND) application until 2020, from late 2019.
Researchers from Van Andel Research Institute, based in Grand Rapids, Mich., found that people who had appendicitis resulting in the removal of the organ, had a lower risk of developing Parkinson’s disease later in life.
There is increasing evidence that there is some sort of association between sleep problems and dementias such as Alzheimer’s disease. This was further linked with a recent research study published in the journal Sleep.
-- Intratumoral treatment with ilixadencel, an off-the-shelf cell-based immune primer, provides synergistic anti-tumor effect and enhances efficacy of anti-PD-1 and anti-CD137 treatment in animal model --
Yesterday, researchers at the Massachusetts Institute of Technology (MIT) published research in the journal Science Advances describing yet another CRISPR improvement.
PRESS RELEASES